{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:50:54Z","timestamp":1783813854712,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.leukres.2012.03.003","type":"journal-article","created":{"date-parts":[[2012,4,2]],"date-time":"2012-04-02T12:02:04Z","timestamp":1333368124000},"page":"1124-1127","source":"Crossref","is-referenced-by-count":69,"title":["Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis"],"prefix":"10.1016","volume":"36","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.03.003_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2004.02.011","article-title":"The chronic myeloproliferative disorders: clonality and clinical heterogeneity","volume":"41","author":"Spivak","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2012.03.003_bib0010","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.03.003_bib0015","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2012.03.003_bib0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood-2005-06-2413","article-title":"The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor","volume":"107","author":"Lucet","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.03.003_bib0025","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.leukres.2012.03.003_bib0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2012.03.003_bib0035","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.03.003_bib0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2012.03.003_bib0045","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2012.03.003_bib0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.278.278","article-title":"Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: results from COMFORT-I","volume":"118","author":"Verstovsek","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.03.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.279.279","article-title":"Ruxolitinib provides reductions in splenomegaly across subgroups: an analysis of spleen response in the COMFORT-II study","volume":"118","author":"Harrison","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.03.003_bib0060","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/cncr.26359","article-title":"Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms","volume":"118","author":"Quintas-Cardama","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2012.03.003_bib0065","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2012.03.003_bib0070","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/77819","article-title":"SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression","volume":"1","author":"Herblot","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.leukres.2012.03.003_bib0075","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3292.3292","article-title":"Phase I study of the oral histone deacetylase inhibitor SB939 in patients with advanced hematologic malignancies","volume":"116","author":"Garcia-Manero","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.03.003_bib0080","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.leu.2404007","article-title":"Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"20","author":"McClure","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.03.003_bib0085","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.03.003_bib0090","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2012.03.003_bib0095","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.630.630","article-title":"A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis","volume":"116","author":"DeAngelo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.03.003_bib0100","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.798.798","article-title":"Improved efficacy upon combined JAK1\/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease","volume":"118","author":"Baffert","year":"2011","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T15:42:05Z","timestamp":1713800525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0145212612001257"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.03.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}